enGene
Martine Bail is a seasoned research scientist with over 19 years of experience in biochemistry, molecular medicine, and scientific research. Currently serving as a Research Scientist I at enGene since May 2018, Martine has contributed to the development of cell culture models and IND-enabling studies for EG-70. Previous roles include positions at Collège Bourget as a substitute professor, and at Polytechnique Montréal focusing on in vitro assay techniques and the development of nucleic acid therapeutics. Prior experience at the Institute for Research in Immunology and Cancer involved the management of research projects related to nuclear receptors and breast cancer. Martine holds a Master of Science in Biochemistry and Molecular Medicine from Université de Montréal, as well as a Certificate of Graduate Studies in Business Administration from Université Laval.
enGene
enGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility including DNA and various forms of RNA (siRNA, shRNA, lncRNA etc.) with broad tissue and disease applications